Last reviewed · How we verify

NCT05654792: ProgNOP-LBBB

Prognostic Factors in NOP-LBBB After TAVI

Status unknown Last updated 16 December 2022
What this trial tests

trial testing Transcatheter aortic valve implantation in Transcatheter Aortic Valve Replacement in 230 participants. Status unknown.

Timeline
10 December 2022
Primary endpoint
1 May 2023
1 May 2023

Quick facts

Lead sponsorCentral Hospital, Nancy, France
StatusStatus unknown
Study typeOBSERVATIONAL
Enrollment230
Start date10 December 2022
Primary completion1 May 2023
Estimated completion1 May 2023

Drugs / interventions tested

Conditions studied

Sponsor

Central Hospital, Nancy, France

Who can join

Eligibility, any sex, with Transcatheter Aortic Valve Replacement. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The goal of this observational study is to find prognostic factors in patients with a new-onset persistent left bundle branch block (NOP-LBBB) after transcatheter aortic valve implantation (TAVI). The main question it aims to answer is: Are there any factors influencing heart failure or death risk during the year following TAVI in patients with NOP-LBBB ? Participants will have data collection about TAVI procedure and clinical evolution during a one-year follow-up.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Transcatheter aortic valve implantation

Trials testing the same drug.

Other recruiting trials for Transcatheter Aortic Valve Replacement

Currently open trials in the same condition.

Other Central Hospital, Nancy, France trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05654792.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing